INVO Fertility revenue rises 5% as new patent, acquisition anchor growth strategy

INVO Fertility (NASDAQ:IVF) reported a 5% increase in total net revenue for fiscal year 2025, supported by steady expansion across its clinic network and a restructured balance sheet that eliminated several complex legacy equity liabilities.

The medical device and fertility clinic operator posted full-year net revenue of $6.84 million, up from $6.53 million in the prior fiscal year.

When factoring in financial contributions from all owned and managed clinical locations, total clinic-level revenue reached $8.02 million, representing a 4% increase year-over-year.

The top-line expansion helped INVO Fertility narrow its net loss from continuing operations to $5.3 million, a significant improvement compared to the $7.7 million net loss recorded during fiscal year 2024.

Adjusted EBITDA for the year stood at negative $3.2 million, compared to negative $2.2 million in the previous period, reflecting ongoing foundational investments in marketing and clinic integration.

The company executed multiple capital-raising initiatives to improve its long-term financial position and fund near-term commercial activities.

Through a series of targeted financings closed across December 2025 and January 2026, INVO successfully raised approximately $11.5 million in gross cash proceeds.

Management utilized a portion of these inflows to simplify its capital structure, entirely eliminating its outstanding Series C-2 preferred stock obligations alongside related warrant liabilities.

Following these capital adjustments, the company reported approximately 1.8 million common shares outstanding.

Operationally, INVO advanced its regional clinical consolidation strategy by finalizing the acquisition of Indiana-based fertility clinic Family Beginnings in February 2026.

The transaction expands the company's delivery network for its proprietary intravaginal culture system.

Concurrently, the firm strengthened its intellectual property portfolio by securing a new utility patent from the U.S. Patent and Trademark Office for a modified iteration of its core INVOcell device.